MCID: BNG030
MIFTS: 53

Benign Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Benign Ependymoma

MalaCards integrated aliases for Benign Ependymoma:

Name: Benign Ependymoma 12 15
Ependymoma 45 74
Who Grade Ii Ependymal Tumor 12
Myxopapillary Ependymoma 74
Epithelial Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4844
MeSH 45 D004806
NCIt 51 C3017
SNOMED-CT 69 57706008

Summaries for Benign Ependymoma

MalaCards based summary : Benign Ependymoma, also known as ependymoma, is related to anaplastic ependymoma and cellular ependymoma, and has symptoms including back pain An important gene associated with Benign Ependymoma is TSC2 (TSC Complex Subunit 2), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and AMP-activated Protein Kinase (AMPK) Signaling. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are behavior/neurological and nervous system

Related Diseases for Benign Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Benign Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 anaplastic ependymoma 33.9 GFAP NF2 SYP
2 cellular ependymoma 33.7 GFAP SYP
3 malignant ependymoma 33.6 GFAP NF2
4 clear cell ependymoma 33.4 ENO2 GFAP SYP
5 spinal cord ependymoma 33.2 EPB41L3 NF2
6 papillary ependymoma 32.9 ENO2 GFAP RBFOX3 SYP
7 tanycytic ependymoma 32.8 GFAP NF2 RBFOX3 SYP
8 subependymoma 31.9 ENO2 GFAP SYP TSC2
9 neurofibromatosis, type ii 31.5 EPB41L3 NF2
10 papilloma of choroid plexus 30.5 GFAP SYP
11 angiocentric glioma 30.3 GFAP SYP
12 subependymal glioma 30.3 ENO2 GFAP KCTD1 MTOR SYP TSC1
13 spinal meningioma 30.3 ENO2 NF2
14 hydrocephalus 30.2 ENO2 GFAP SYP
15 hemangioblastoma 30.2 ENO2 GFAP SYP
16 oligodendroglioma 30.1 ENO2 GFAP SYP
17 teratoma 30.1 ENO2 GFAP SYP
18 atypical teratoid rhabdoid tumor 30.1 GFAP SYP
19 chordoid meningioma 30.0 GFAP SYP
20 medulloepithelioma 30.0 GFAP SYP
21 renal cell carcinoma, nonpapillary 29.9 MTOR TSC1 TSC2
22 neurilemmoma 29.9 ENO2 GFAP NF2
23 gangliocytoma 29.9 RBFOX3 SYP
24 rhabdoid cancer 29.8 ENO2 SYP
25 carcinoid syndrome 29.7 ENO2 SYP
26 astroblastoma 29.6 ENO2 GFAP SYP
27 central neurocytoma 29.6 ENO2 GFAP SYP
28 cystic teratoma 29.6 ENO2 GFAP SYP
29 ganglioneuroma 29.6 ENO2 GFAP SYP
30 ganglioglioma 29.6 ENO2 GFAP SYP TSC2
31 neuroma 29.5 ENO2 GFAP NF2
32 ependymoma 29.3 ENO2 GFAP NF2 SYP
33 tuberous sclerosis 29.2 GFAP MTOR SYP TSC1 TSC2
34 meningioma, familial 29.1 ENO2 EPB41L3 GFAP NF2 SYP
35 myxopapillary ependymoma 12.6
36 pediatric ependymoma 12.5
37 pediatric supratentorial ependymoma 12.3
38 adult brain ependymoma 12.3
39 brain ependymoma 12.2
40 pediatric infratentorial ependymoma 12.2
41 rela fusion-positive ependymoma 12.2
42 brain stem ependymoma 12.0
43 malignant adult ependymoma 12.0
44 adult spinal cord ependymoma 12.0
45 mixed astrocytoma-ependymoma-oligodendroglioma 12.0
46 mixed astrocytoma-ependymoma 12.0
47 parietal lobe ependymoma 12.0
48 glioma susceptibility 1 11.6
49 medulloblastoma 11.4
50 glioma 11.4

Graphical network of the top 20 diseases related to Benign Ependymoma:



Diseases related to Benign Ependymoma

Symptoms & Phenotypes for Benign Ependymoma

UMLS symptoms related to Benign Ependymoma:


back pain

MGI Mouse Phenotypes related to Benign Ependymoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.56 ENO2 EPB41L3 GFAP MTOR NF2 SYP
2 nervous system MP:0003631 9.23 ENO2 EPB41L3 GFAP MTOR NF2 SYP

Drugs & Therapeutics for Benign Ependymoma

Drugs for Benign Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
3
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
4
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
6
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
7
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
8
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
9
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
10
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Donepezil Approved Phase 3,Phase 2,Early Phase 1 120014-06-4 3152
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
17
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
18
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
19
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
20
Dopamine Approved Phase 3,Phase 2,Early Phase 1,Not Applicable 62-31-7, 51-61-6 681
21
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
23 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
24 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
25
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
26 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Folate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
44 Keratolytic Agents Phase 3,Phase 2,Phase 1
45 Podophyllotoxin Phase 3,Phase 2,Phase 1 518-28-5
46 Narcotics Phase 3
47 Adjuvants, Anesthesia Phase 3
48 Analgesics Phase 3,Phase 2,Phase 1
49 Anesthetics, Intravenous Phase 3
50 Liver Extracts Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 265)
# Name Status NCT ID Phase Drugs
1 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
2 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
3 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
8 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
11 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
12 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
13 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
14 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
15 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
16 Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
17 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
18 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
19 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
20 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
22 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
23 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
24 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
25 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
26 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
27 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
28 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
29 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
30 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
31 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
32 A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Completed NCT00187226 Phase 2
33 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2 Everolimus (RAD001) , Afinitor®
34 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
35 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
36 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
37 A Phase I/II Study of the Photon Radiosurgery System Completed NCT00179907 Phase 1, Phase 2
38 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
39 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
40 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
41 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
42 Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy Completed NCT00463203 Phase 2 Bevacizumab;Irinotecan
43 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
44 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
45 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
46 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
47 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
48 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
49 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
50 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy

Search NIH Clinical Center for Benign Ependymoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: ependymoma

Genetic Tests for Benign Ependymoma

Anatomical Context for Benign Ependymoma

MalaCards organs/tissues related to Benign Ependymoma:

42
Brain, Spinal Cord, Bone, Kidney, T Cells, Bone Marrow, Liver

Publications for Benign Ependymoma

Articles related to Benign Ependymoma:

(show top 50) (show all 1457)
# Title Authors Year
1
Microsurgical Resection of Anaplastic Ependymoma of the Cerebellopontine Angle in an Adult: 3-Dimensional Operative Video. ( 30295880 )
2019
2
Sudden Unexpected Death in a Child From an Anaplastic Ependymoma. ( 30958386 )
2019
3
Anaplastic ependymoma arising from the lower segment of the uterine corpus: Case report and literature review. ( 31060102 )
2019
4
A Case of Recurrent Supratentorial Extraventricular Anaplastic Ependymoma in Adult. ( 31062531 )
2019
5
Destructive arthropathy of the shoulder complicating a cervical ependymoma. ( 30890366 )
2019
6
A systematic review of outcome in intramedullary ependymoma and astrocytoma. ( 30833131 )
2019
7
Natural Course of Myxopapillary Ependymoma: Unusual Case Report and Review of Literature. ( 30321682 )
2019
8
Unusual features of ependymoma in a patient with Parkinson's disease. ( 30409527 )
2019
9
Long-Term Supratentorial Radiologic Effects of Surgery and Local Radiation in Children with Infratentorial Ependymoma. ( 30448581 )
2019
10
Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. ( 30452715 )
2019
11
Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. ( 30460634 )
2019
12
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma. ( 30483834 )
2019
13
Radiosurgery or hypofractionated stereotactic radiotherapy after craniospinal irradiation in children and adults with medulloblastoma and ependymoma. ( 30515559 )
2019
14
Surgical outcome in cortical ependymoma: A single centre experience of 18 cases. ( 30528353 )
2019
15
Individualized treatment for a case of recurrent ovarian ependymoma. ( 30588035 )
2019
16
Management of Ependymoma in Children, Adolescents and Young Adults. ( 30616927 )
2019
17
A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review. ( 30631904 )
2019
18
Clinical Characteristics and Prognostic Factors of Treatment in Pediatric Posterior Cranial Fossa Ependymoma. ( 30699434 )
2019
19
To Treat, or Not to Treat, That is the Question for a 13-Month-Old Girl with Cranial Ependymoma and an Unknown Spinal Mass. ( 30712706 )
2019
20
Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. ( 30768777 )
2019
21
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. ( 30811284 )
2019
22
Re-irradiation of locally recurrent pediatric intracranial ependymoma: Experience of the French society of children's cancer. ( 30825956 )
2019
23
Myxopapillary Ependymoma. ( 30844350 )
2019
24
Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. ( 30850560 )
2019
25
The value of high-dose radiotherapy in intracranial ependymoma. ( 30865382 )
2019
26
Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues. ( 30868390 )
2019
27
Spinal melanotic ependymoma: A case report and review of literature. ( 30871914 )
2019
28
Ependymoma of the spinal cord in children. A Retrospective French study. ( 30877001 )
2019
29
Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. ( 30883662 )
2019
30
Quantitative Analysis of Near-Infrared Indocyanine Green Videoangiography for Predicting Functional Outcomes After Spinal Intramedullary Ependymoma Resection. ( 30888018 )
2019
31
EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. ( 30923826 )
2019
32
Papillary Ependymoma of the Spinal Cord: A Case Report with Summary of Prior Published Cases. ( 30937039 )
2019
33
Cerebellopontine angle ependymoma in a young adult: A case report. ( 30946332 )
2019
34
Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. ( 30976811 )
2019
35
Spinal Cord Ependymoma - Surgical Management and Outcome. ( 31001024 )
2019
36
Extramedullary Tanycytic Ependymoma in a 12-Year-Old Boy. ( 31001044 )
2019
37
High-dose chemotherapy with autologous stem cell transplantation in infants and young children with ependymoma: A 10-year experience with the Head Start II protocol. ( 31012212 )
2019
38
Resection of Myxopapillary Ependymoma of the Filum Terminale: 2-Dimensional Operative Video. ( 31073602 )
2019
39
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. ( 31086175 )
2019
40
NF2 and ATRX gene copy number losses on a case of ovarian ependymoma. ( 29944970 )
2019
41
High Cervical Ependymoma Resection: 2-Dimensional Operative Video. ( 30107551 )
2019
42
Rapid autopsy of a patient with recurrent anaplastic ependymoma. ( 28942746 )
2018
43
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. ( 29063976 )
2018
44
Adult Supratentorial Extraventricular Anaplastic Ependymoma: Therapeutic Approach and Clinical Review. ( 29492136 )
2018
45
Pediatric Isolated Cortical (Ectopic) Anaplastic Ependymoma. ( 29492147 )
2018
46
Radiation necrosis following proton therapy successfully treated by low-dose bevacizumab in a patient with relapsed anaplastic ependymoma. ( 29667785 )
2018
47
Pineal Anaplastic Ependymoma With Multifocal Intradural Extramedullary Metastases on MRI and 18FDG-PET. ( 30080187 )
2018
48
Preoperative and intraoperative perfusion magnetic resonance imaging in a RELA fusion-positive anaplastic ependymoma: A case report. ( 30105138 )
2018
49
Pediatric Case of Li-Fraumeni Syndrome Complicated with Supratentorial Anaplastic Ependymoma. ( 30196175 )
2018
50
Intramedullary spinal cord ependymoma and astrocytoma: intraoperative frozen-section diagnosis, extent of resection, and outcomes. ( 30485241 )
2018

Variations for Benign Ependymoma

Expression for Benign Ependymoma

Search GEO for disease gene expression data for Benign Ependymoma.

Pathways for Benign Ependymoma

Pathways related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 MTOR NF2 TSC1 TSC2
2
Show member pathways
12.21 MTOR TSC1 TSC2
3
Show member pathways
12.19 MTOR TSC1 TSC2
4
Show member pathways
12.17 MTOR TSC1 TSC2
5
Show member pathways
12.16 MTOR TSC1 TSC2
6
Show member pathways
12.07 MTOR TSC1 TSC2
7 12.02 MTOR TSC1 TSC2
8
Show member pathways
11.98 MTOR TSC1 TSC2
9
Show member pathways
11.95 MTOR TSC1 TSC2
10 11.9 MTOR TSC1 TSC2
11 11.89 ENO2 GFAP NF2 RBFOX3 SYP
12 11.88 MTOR TSC1 TSC2
13 11.87 MTOR TSC1 TSC2
14
Show member pathways
11.85 MTOR TSC1 TSC2
15
Show member pathways
11.83 MTOR TSC1 TSC2
16 11.72 MTOR TSC1 TSC2
17 11.51 MTOR TSC1 TSC2
18 11.33 MTOR TSC1 TSC2
19 11.22 MTOR TSC1 TSC2
20 11.07 MTOR TSC2
21 11.06 MTOR TSC1 TSC2
22 11 MTOR TSC2
23 10.97 MTOR NF2 TSC1 TSC2
24 10.86 MTOR TSC1 TSC2
25 10.71 MTOR TSC1

GO Terms for Benign Ependymoma

Cellular components related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynaptic density GO:0014069 9.13 EPB41L3 TSC1 TSC2
2 TSC1-TSC2 complex GO:0033596 8.62 TSC1 TSC2

Biological processes related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell cycle GO:0051726 9.54 NF2 TSC1 TSC2
2 negative regulation of TOR signaling GO:0032007 9.48 TSC1 TSC2
3 negative regulation of insulin receptor signaling pathway GO:0046627 9.46 TSC1 TSC2
4 positive regulation of macroautophagy GO:0016239 9.43 TSC1 TSC2
5 regulation of protein kinase activity GO:0045859 9.4 MTOR TSC1
6 positive regulation of glial cell proliferation GO:0060252 9.32 GFAP MTOR
7 negative regulation of macroautophagy GO:0016242 9.26 MTOR TSC1
8 anoikis GO:0043276 9.16 MTOR TSC2
9 negative regulation of cell size GO:0045792 8.96 MTOR TSC1
10 positive regulation of stress fiber assembly GO:0051496 8.8 MTOR NF2 TSC1

Molecular functions related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Hsp90 protein binding GO:0051879 8.62 TSC1 TSC2

Sources for Benign Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....